key: cord-0298474-5q7np5mg
authors: Kirby, J. E.; Riedel, S.; Dutta, S.; Arnaout, R.; Cheng, A.; Ditelberg, S.; Hamel, D. J.; Chang, C. A.; Kanki, P. J.
title: SARS-CoV-2 Antigen Tests Predict Infectivity Based on Viral Culture: Comparison of Antigen, PCR Viral Load, and Viral Culture Testing on a Large Sample Cohort
date: 2021-12-23
journal: nan
DOI: 10.1101/2021.12.22.21268274
sha: c00869679c51d9cf21572a45111f5e3469ab2de2
doc_id: 298474
cord_uid: 5q7np5mg

The relationship of SARS-CoV-2 antigen testing results, viral load, and viral culture detection remains to be fully defined. Presumptively, viral culture can provide a surrogate measure for infectivity of sampled individuals, and thereby inform how and where to most appropriately deploy available diagnostic testing modalities. We therefore determined the relationship of antigen testing results from three lateral flow and one microfluidics assay to viral culture performed in parallel in 181 nasopharyngeal swab samples positive for SARS-CoV-2. Sample viral loads, determined by RT-qPCR, were distributed across the range of viral load values observed in our testing population. We found that antigen tests were predictive of viral culture positivity, with the LumiraDx method showing enhanced sensitivity (90%; 95% confidence interval (95% CI) 83-94%) compared with the BD Veritor (74%, 95% CI 65-81%), CareStart (74%, 95% CI 65-81%) and Oscar Corona (74%, 95% CI 65-82%) lateral flow antigen tests. Antigen and viral culture positivity were also highly correlated with sample viral load, with areas under the receiver?operator characteristic curves (ROCs) of 0.94-0.97 and 0.92, respectively. In particular, a viral load threshold of 100,000 copies/mL was 95% sensitive (95% CI, 90-98%) and 72% specific (95% CI, 60-81%) for predicting viral culture positivity. Taken together, the detection of SARS-CoV-2 antigen identified highly infectious individuals, some of whom may harbor 10,000-fold more virus in their samples than those with any detectable infectious virus. As such, our data support use of antigen testing in defining infectivity status at the time of sampling.

Ongoing management of the SARS-CoV-2 pandemic will require judicious use of 54 available diagnostic testing modalities. Testing may be used in two general contexts, either for 55 diagnosis of symptomatic illness or to identify asymptomatic carriers so that appropriate 56 isolation precautions can be instituted and thereby mitigate the infectious risk to others. 57

There are two major SARS-CoV-2 diagnostic technologies: (1) nucleic acid amplification 58 tests (NAATs), typically real-time polymerase chain reaction tests (PCR), and (2) antigen tests, 59 which generally detect the presence of viral nucleocapsid (N) antigen. For the purposes of 60 discussion, we will use PCR to represent all types of NAAT tests, recognizing that there are 61 several widely used alternative detection technologies such as transcription mediated 62 amplification. PCR tests are highly sensitive, and generally target conserved regions in more 63 than one viral gene to ensure robustness even in the context of ongoing evolution of genetic 64 variants. However, they are expensive compared to antigen tests and have slower turn-around 65 time (TAT) when performed on large automated diagnostic platforms, which are usually located 66 in central laboratories. Most antigen tests currently on the market are based on lateral flow 67 immunoassay methods and detect the conserved N protein (1). In contrast to NAAT tests, antigen 68 tests are fast, highly amenable to point-of-use, and inexpensive. Although antigen tests have 69 lower sensitivity compared with PCR tests, it should be noted that antigen and PCR tests detect 70 different components of the SARS-CoV-2 virus, neither of which may necessarily reflect live 71 replicating virus. 72

With regard to appropriate selection and use of these alternative testing modalities, the 73 ultimate question is how sensitive does a test need to be to serve specific goals of the pandemic 74 response, given cost constraints and speed of testing requirements. A test with lower sensitivity 75 may offer compelling benefit if it were able to reliably identify individuals who present an 76 immediate infectious risk to others. Arguably, more frequent and repetitive testing of individuals 77 using a test with lower sensitivity, may provide equivalent utility to more sensitive NAAT 78 technology at lower cost and greater convenience (2). 79

An individual's infectivity presumptively may be approximated by the infectivity of a 80 diagnostic sample. Diagnostic samples may contain viable virus, non-viable/non-replicating 81 virus components, and/or free viral nucleic acid. Antigen and PCR tests target different 82 components of the SARS-CoV-2 virus, and detection by either technology does not necessarily 83 reflect the presence of replication-competent, infectious virus and therefore infectiousness. 84

However, viable virus can be cultured, i.e., it will infect and replicate in tissue culture cells. 85

Therefore, tissue culture assays can provide an assessment of the presence and amount of viable 86 virus, and, by inference, the infectivity of individuals from whom samples were obtained. 87 Therefore, we sought to compare the results of antigen and quantitative PCR viral load 88 determination with viral culture detection of SARS-CoV-2 to further inform decisions on best 89 utilization of antigen and PCR testing. 90 91

In our study design, the same patient specimens were tested by reverse-transcription 93 (RT)-qPCR; antigen detection using four different commercial methods, three with FDA 94 Emergency Use Authorization; and viral culture for SARS-CoV-2. This avoided the need for six 95 separate sample collections from each patient and the inherent variation introduced during 96 collection of multiple specimens from the same individual (3). Of note, typically, the instructions 97 for use (IFU) for antigen tests indicate that sample from a single nasal collection swab should be 98 loss of detection of viable virus in samples with viral loads of less than ~10 5 genome copies/mL 122 ( Fig. 1) . 123

Distributions of viral load results determined by RT-qPCR in samples, testing positive or 124 negative, respectively, by respective antigen tests are shown in Fig. 2 . Lateral flow assay (LFA)-125 based antigen tests detected samples with a viral load > ~10 7 genome copies/mL, with the 126 exception of a small number of outliers. The microfluidic LumiraDx test detected samples with 127 lower viral loads compared to the other antigen testing methods with a cutoff for consistent 128 detection closer to 10 6 genome copies/mL. Differences between log 10 transformed mean viral 129 loads of samples positive by LumiraDx and positive by each of the LFA methods, respectively, 130

were statistically significant for all pairwise comparisons (adjusted P < 0.05), as were differences 131 in (geometric) mean viral loads of samples testing negative by LumiraDx and negative by each 132 of the LFA methods, respectively, using the Holm-Sidak's multiple comparison test. However, 133 BD Veritor, CareStart and Oscar Corona tests were indistinguishable in all pairwise comparisons 134 with one another (adjusted P = 0.99). 135

Receiver-operator characteristic curves (ROC) were plotted to determine the viral load 136 cutoffs which would reasonably predict detection by viral culture and antigen testing, 137 respectively ( Fig. 3) . Notably, a viral load cutoff of ~10 5 was highly sensitive for predicting a 138 positive viral culture without undue loss of specificity. A viral load cutoff of ~10 4 -10 5 was 139 reasonably sensitive for predicting a positive LumiraDx result without undue loss of specificity. 140 Viral load cutoffs of 10 5 -10 6 likewise were reasonably predictive of positive BD, Oscar and 141

CareStart test results. The ROC area under the curve (AUC) was > 0.94 for all comparisons (Fig.  142 3B-E), indicating that viral loads could serve as a reasonable surrogate for predicting the 143 presence of culturable infectious virus and detectable antigen (and vice versa). Notably, viral 144 load cutoffs for detecting positive viral cultures and positive antigen tests were similar, further 145 supporting similar qualitative detection by viral culture and antigen tests. 146

Three hundred SARS-CoV-2 RT-qPCR negative samples were also tested by all four 147 antigen tests. All antigen tests were negative, supporting high specificity of the antigen assays. 148 149

The evolving COVID-19 pandemic has brought a growing need for more and diverse 151 diagnostic test methods. The detection of SARS-CoV-2 RNA by RT-qPCR is the gold standard 152 for laboratory diagnosis of COVID-19, yet it is well recognized that the assay may detect RNA 153 fragments or viral debris that do not correlate with viable infectious virus. For example, in the 154 Syrian golden hamster model, transmissibility of SARS-CoV-2 correlated well with detection of 155 infectious virus by culture, but not with positive RNA results by qPCR (4). Therefore, qPCR 156 may identify a large number of patients who are infected, but who may not necessarily be 157 infectious to others. SARS-CoV-2 viral culture may be a better surrogate of infectivity, but is 158 currently impractical and rarely used as a primary testing modality due to its stringent biosafety 159 requirements (Biosafety Level 3; BL3) requirements, assay complexity, and low throughput (5, 160 6). 161

Antigen test methods are an inexpensive and more rapid test method compared to most 162 NAAT tests and are amenable to point-of-care settings, for example, use at schools and for self-163 testing. We therefore compared performance of antigen tests to PCR and viral culture to assess 164 the ability of antigen tests to identify infected and infectious individuals. Our general findings 165

were that antigen tests largely predicted ability to culture live virus. Furthermore, culture and 166 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 23, 2021. ; https://doi.org/10. 1101 antigen tests were both consistently positive at higher viral loads as determined by negative at lower viral loads. 168

Previous studies have also correlated viral culture with qPCR testing, describing positive 169 cultures from upper respiratory tract samples between 6-9 days after infection (6-9). In our study, 170 a viral load of cutoff of 100,000 copies/mL was 95% sensitive (95% CI, 90-98%) and 72% 171 specific (95% CI, 60-81%) for predicting viral culture positivity. Other studies of SARS-CoV-2 172 culture have reported similar findings, where viable virus culture was described from samples 173 with 250,000-1,000,000 copies/mL (9, 10) or expressed alternatively as cycle threshold (Ct) 174 value cutoffs of 24-35 (11, 12) . Note, we converted from Ct values to viral loads (in units of 175 genome copies/mL), since Ct values cannot be compared from assay to assay (3). 176

Presumptively, individuals with the highest amount of culturable virus pose the greatest 177 degree of infectivity and risk to others. It should be stressed that viral loads for SARS-CoV-2 178 vary over nine orders of magnitude. The difference between the lowest viral loads, where virus is 179 consistently detected by culture (10 5 copies/mL, Fig. 1, 3) , and the highest observed viral loads 180 (~1 billion copies/mL) is at least four orders of magnitude. Furthermore, above the viral culture 181 detection threshold, we found that the amount of viable virus in day 3 culture supernatants was 182 roughly proportional to sample viral load determined by qPCR ( Fig. 1) , suggesting that the large 183 range of viral loads determined by RT-qPCR corresponds to the range and degree of sample 184 infectivity. Importantly, antigen test sensitivity is noted to be near 100% in the upper three orders 185 of magnitude of viral loads observed (Fig. 2, 3, 4) , suggesting that antigen tests are quite good in 186 detecting individuals who shed larger amounts of virions and therefore would pose significant 187 risk to others during casual contact. 188 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 23, 2021. ; https://doi.org/10. 1101 It has been argued by some that Ct values should not be made available to providers 189 based on a number of reasons, including differences in the correlation between Ct and viral load 190 generated from different assays (reviewed in (13)). Our data support the meaningful association 191 of viral load with infectivity, and therefore further argue for conversion of ambiguous Ct values 192

to unambiguous viral loads, calibrated to a universal standard, as we have proposed previously 193

Interestingly, the viral load threshold associated with consistent LFA detection in our 195

clinical samples was similar to the previously described analytical limit of detection (LoD) of the 196 Quidel Sofia antigen test determined using SARS-CoV-2 infected Vero cell quality control 197 material (14). The LoD for the Sofia test in viral genome copies/mL was inferred from the 198 TCID 50 provided by the manufacturer in its Instructions for Use (IFU) (14), and the conversion 199 factor between TCID 50 and viral genome copies/mL provided in documentation for the lots 200 (70033548, 70034991) of BEI Resources, NR-52286 quality control material available during 201 the time the IFU studies were performed (3, 14) . This correspondence suggests that quantitative 202 relationships between detectable antigen and viral genomic material are similar for human 203 nasopharyngeal specimens and virus grown in cell culture. 204

Our study design had several strengths as well as some limitations. It is known that there 205 may be variability in results obtained from repeat sampling of the same patient, for example, due 206 to collection technique (3, 15). We sought to eliminate this source of confounding variability by 207 performing antigen, RT-qPCR, and viral culture testing on the same samples. Therefore, the per 208 sample performance characteristics of each methodology could be directly compared. 209

However, this led to the need to perform antigen testing outside of direct swab sampling 210 testing recommendations, potentially leading to underestimation of antigen test sensitivity. Based 211 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 23, 2021. ; on the dilution factor in viral transport medium, and the amount of sample used in antigen testing 212 in our study, we estimate that antigen tests, had they been performed by directly eluting swab 213 samples into antigen test extraction buffer, would have detected samples with approximately 17 214 to 18-fold lower viral loads. As such, the antigen tests would have identified samples from 215 individuals with the lowest viral loads associated with a positive viral culture. For example, we 216 estimate that if swab samples were tested directly without dilution in viral transport medium, 217

LFA antigen tests would have reliably detected individuals with viral loads > ~550,000 genome 218 copies/mL, and the LumiraDx test would have reliably detected individuals with viral loads > 219 ~60,000 copies/mL (see Fig 2) . It is possible though that this estimate is too high or too low 220 based on pre-analytical (e.g., sample elution efficiency) and analytical variables not appreciated. 221

Both a strength and weakness of the approach was the selection of samples based on the 222 distribution of viral loads observed during clinical testing (3). Samples were not selected based 223 on patients' clinical symptoms, timing of symptoms, and potential exposures. Our testing centers 224 obtain samples from community and hospital settings, both for diagnosis of illness and screening 225 purposes. Thus, this is likely to reflect a real-world situation in which testing is performed for a 226 variety of purposes. Therefore, without knowledge of the purpose and timing of specimen 227 collection, it is possible that results may not be fully representative of performance 228 characteristics in all diagnostic settings. Also, samples were obtained in March through June 229 2021 prior to emergence of the Delta or Omicron variants in our region. Relationships between 230 viral load, antigen, and culture results are likely to be maintained. However, experimental 231 verification during emergence of current and future variants would be desirable. Lastly, we used 232 nasopharyngeal swab samples rather than nasal swab samples that are more often used for 233 antigen testing assays. Of note, we previously found in a clinical trial, in which nasal swabs and 234 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 23, 2021. ; nasopharyngeal swabs were collected from the same patients in parallel, that viral loads between 235 these sample types were congruent for samples with viral loads > 1000 genome copies/mL (15), 236 the range of interest in our study. Therefore, we believe that the use of nasopharyngeal swabs 237 necessitated by our study design had negligible impact on our comparisons. 238

One goal was to determine whether gaps in specificity for each antigen testing method 239 (i.e., false positive results) would or would not overlap. If the latter were found, then antigen 240 tests could potentially be used sequentially for screening and confirmatory analysis. However, no 241 false positives were noted for any method. Therefore, the number of samples analyzed was 242 insufficient to address whether further improvements in aggregate specificity could be achieved 243 by use of tandem antigen testing strategies. It is possible that our sampling strategy, resulting in 244 specimen dilution compared with direct nasal sampling, may have been biased towards increased 245

Three of the antigen assays analyzed in our study (BD Veritor, CareStart, and Oscar 247 Corona) were chromatographic LFAs. The BD Veritor system interprets results using an 248 automated reader, while the CareStart and Oscar Corona assays was read visually. The Oscar 249

Corona assay is not approved for use in the United States, but is widely used in India. The 250 performance of these three assays in our study was essentially identical. In contrast, the 251 LumiraDx assay used a microfluidic immunofluorescent detection technology and appeared 252 significantly more sensitive than the other antigen test methods (see Fig. 1-3, Table 1 ), consistent 253 with high level detection of infected patients during the first twelve days of symptom onset, as 254 previously described, using PCR as the gold standard for infection (16). The observed lower 255 sensitivity of antigen tests relative to PCR has also been described previously (17) (18) (19) (20) . 256 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 23, 2021. ; https://doi.org/10. 1101 Informed use of SARS-CoV-2 testing is crucial to current and future control of the 257 SARS-CoV-2 pandemic. The available testing options have different attributes in terms of TAT, 258 potential for point-of-care deployment, cost, and performance. Our study finds that inexpensive, 259 point-of-care deployable LFA assays have sufficient sensitivity to detect individuals whose 260 diagnostic samples contain culturable virus and who therefore pose a potential transmission risk 261 to others (Fig. 4) . The performance characteristics of these LFA tests are outstanding in 262 identifying the most highly infectious specimens. This attribute may be especially important 263 during the SARS-CoV-2 Delta variant surge, characterized by individuals with viral load skewed 264 to even higher levels, whether symptomatic or asymptomatic (21, 22) . 265

Therefore, our data support use of antigen testing to identify infectious individuals at the 266 time of sampling. These tests would presumably be highly efficacious at identifying and 267 allowing isolation of significantly infectious individuals from communal events, same-day 268 healthcare procedures, communal travel arrangements, and other settings with significant person-269 to-person contact where universal masking is not feasible or desired, as has been demonstrated in 270 recent epidemiological studies (23). As a point-of-use testing modality, results can be 271 immediately available and inform timely mitigation of infectious risk to others and/or clinical 272 management. However, the sensitivity of antigen tests is low relative to PCR. They, therefore, 273

will not identify recently infected individuals whose viral load and infectious burden has yet to 274 climb into a detectable range, nor identify patients who have been infected in the recent past and 275 whose results may inform contact tracing efforts. Accordingly, antigen tests lack the power of 276 PCR for screening programs intended to secure populations through regular testing at longer 277 spaced time intervals and testing of patients being admitted to hospitals where the best available 278 analytical sensitivity is desirable to prevent outbreaks in at risk populations. The improved 279 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 23, 2021. ; https://doi.org/10. 1101 detection by the LumiraDx test shows that new testing modalities should be evaluated on a 280 sliding scale relative to a quantitative standard such as viral load, for as in this case, they may 281 provide an enhanced safety zone for screening individuals who will have contact with vulnerable 282 populations or healthcare settings. 283

The identification of individuals at high risk for transmitting SARS-CoV-2 is a major 284 public health goal to limit community spread. While viral culture may be the standard diagnostic 285 method to determine infectivity; cost, complexity, and BL3 requirements prohibit its use as a 286 routine clinical diagnostic method. Overall, our study supports use of antigen detection tests for 287 specific purposes, where immediate detection of potential infectivity and especially highly 288 infectious individuals is desired. Furthermore, although significantly less sensitive than PCR for 289 detecting infected individuals, they provide a point-of-use alternative which may, through 290 repeated testing at closely spaced time intervals and more rapid results, provide equivalent power 291 to address goals of the pandemic at much lower cost. were collected at drive-through testing sites in Boston and several surrounding communities 300 affiliated with our medical center (15). After PCR testing for clinical purposes, samples were 301 stored at 4ºC until testing by viral culture and antigen testing. Human subjects research in this 302 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 23, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Delhi, India) SARS-CoV-2 antigen tests were performed according to the manufacturer's 326 instructions with the exception that 250 uL of patient sample (nasopharyngeal swab sample 327 eluted into 3 mL of saline or viral transport medium) was pipetted into the extraction vial 328 provided with each kit rather than direct insertion of the nasal swab into the extraction vial. The 329

LumiraDx test contained ~600 uL of extraction buffer; the other methods used ~500 uL of 330 extraction reagent. Therefore, approximate dilution of sample compared with direct sample 331 assuming complete elution from direct swab sampling was ~17 fold for the Lumira method and 332 ~18-fold for the other antigen test methods. containing 1% antibiotic-antimycotic, 1% HEPES and 5% fetal calf serum (FCS, Gibco), and 336 grown to confluence at approximately 1 x 10 6 cells per well (9-11). 337

Vero E6 cells were inoculated with 250ul of patient sample and incubated at 37ºC for 24 338 hours for viral adsorption. Simultaneously, a negative control was also inoculated with 250uL of 339 viral growth media. Carryover of non-viable viral RNA present in samples was limited by 340 washing cell cultures after the 24-hour viral adsorption and adding fresh EMEM composite 341 media with reduced FCS to 2% for viral growth. Therefore, detectable virus should represent 342 viable replicating virus. On days, 3, 6, and 13-14 days of culture, 800 uL of cell culture 343 supernatant was removed and added to 800 ul of VXL buffer (QIAGEN, German, MD) (1:1 344 ratio) for subsequent nucleic acid extraction and SARS-CoV-2 real-time RT-qPCR. Cultures 345 were re-fed with addition of 1 mL of EMEM with reduced FCS after sampling at each time 346 point. 347

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 23, 2021. ; https://doi.org/10. 1101 Supernatant viral loads below the LoD of the PCR assay were scored negative at that 348 timepoint. Samples with two of three sequential supernatant viral loads exceeding the LoD were 349 considered positive, and, conversely, samples with either one or no viral loads exceeding the 350 LoD were considered negative. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 23, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 23, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 23, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint for each ROC curve is denoted on respective plots. 550 551 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Antigen Tests. Both LumiraDx and lateral flow-based antigen tests (e.g., BD Veritor, CareStart, 561 and Oscar Corona) were able to detect individuals with viable, culturable virus and who 562 therefore pose an immediate infectious risk to others. Dotted lines indicate reliable detection 563 threshold predicted for each method. Presumptively, infectious risk is proportional to the amount 564 of culturable virus which is roughly proportional to the viral load in samples. Antigen tests were 565 excellent in detecting patients with the highest viral loads which may be four to five log10-fold 566

greater than viral loads detected at the lowest levels where virus can be consistently cultured.

PCR and, to a lesser extent, the LumiraDx test can detect individuals before and after the 568 expected infectious period and therefore may be more appropriate for screening programs where 569 regular testing is performed at longer time intervals. The viral load curve shown is for 570

representational purposes and may not reflect viral load kinetics in any specific individual. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 23, 2021. ; https://doi.org/10. 1101 

Lateral flow assays

Test sensitivity is secondary to frequency and turnaround time for 372 COVID-19 screening

The Limit of Detection Matters: The Case for Benchmarking Severe Acute 375

Respiratory Syndrome Coronavirus 2 Testing

Pathogenesis and transmission of 378 SARS-CoV-2 in golden hamsters

Duration of Severe Acute Respiratory 380

SARS-CoV-2) Infectivity: When Is It Safe to Discontinue 381 Isolation?

CoV-2 detection, viral load and infectivity over the course of an infection

Sofia 2 SARS Antigen FIA, Instructions for Use

Performance by Collection Timing, Procedure, and Method of Transport for Patients with 417 SARS-CoV-2

A Rapid, High-Sensitivity SARS-CoV-2

Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: 421 A Clinical Performance Study

Epidemiologic 428

Characteristics Associated With Severe Acute Respiratory Syndrome Coronavirus 2 429 (SARS-CoV-2) Antigen-Based Test Results

Polymerase Chain Reaction (rRT-PCR) Cycle Threshold Values, Subgenomic RNA

Viral Culture Results From University Testing

Analytical sensitivity and specificity of four point of care rapid antigen 435 diagnostic tests for SARS-CoV-2 using real-time quantitative PCR, quantitative droplet 436 digital PCR, and a mass spectrometric antigen assay as comparator methods

Evaluation of accuracy, exclusivity, limit-of-detection and 442 ease-of-use of LumiraDx™: An antigen-detecting point-of-care device for SARS-CoV-2

Correlation of SARS-CoV-2 Nucleocapsid Antigen and RNA Concentrations in 446

Nasopharyngeal Samples from Children and Adults Using an Ultrasensitive

Quantitative measurement of infectious virus in SARS-CoV-2

Delta and Epsilon variants reveals higher infectivity (viral titer:RNA ratio) in 451 clinical samples containing the Delta and Epsilon variants

Daily 463 testing for contacts of individuals with SARS-CoV-2 infection

SARS-CoV-2 transmission in English secondary schools and colleges: an open-label, 465 cluster-randomised trial

A new method for robust quantitative and qualitative 467 analysis of real-time PCR

Large-Scale, In-House Production of Viral Transport Media To Support 470

SARS-CoV-2 PCR Testing in a Multihospital Health Care Network during the COVID-471